Synopsis Tuberculosis is a major global health concern and about 25% of persons worldwide have a latent infection with Mycobacterium tuberculosis. Treatment of latent infection is highly necessary in children in order to reduce the risk of life-threatening forms of the disease and to prevent future M. tuberculosis transmission. In this study, the safety, side-effect profile, and adherence of 4 months of rifampin with 9 months of isoniazid in children was compared in a randomized trial. The present study compares Rifampin and Isoniazid treatment that has better efficacy for the treatment of Latent Tuberculosis in Children.
This week’s “ MED FACT ” discusses the randomized controlled trial from The New England Journal of Medicine, “ Safety and Side Effects of Rifampin versus Isoniazid in Children ”. Authors : Diallo, T.; et. al. Key Takeaways Among children under the age of 18 years, a…
